Skip to main content
Midas Edge

Olema Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

OLMA$7.27-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balances at June 30, 202568,627,886$7$854,194$314$(509,279)$345,236
Stock-based compensation expense, including employee stock purchase plan expense——4,250——4,250
Exercise of stock options24,844—7——7
Net unrealized gain on marketable securities———212—212
Net loss————(42,217)(42,217)
Balances at September 30, 202568,652,730$7$858,451$526$(551,496)$307,488
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income · Deficit · Equity
Balances at December 31, 202474,312,608$7$843,920$143$(435,106)$408,964
Stock-based compensation expense, including employee stock purchase plan expense——13,320——13,320
Issuance of shares under employee stock purchase plan206,609—748——748
Exercise of stock options203,513—477——477
Issuance cost associated with private equity placement——(14)——(14)
Exchange of common stock shares for pre-funded warrants(6,070,000)—————
Net unrealized gain on marketable securities———383383
Net loss————(116,390)(116,390)
Balances at September 30, 202568,652,730$7$858,451$526$(551,496)$307,488

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · (Loss) Income · Deficit · Equity
Balances at June 30, 202457,246,411$4$594,261$(118)(366,984)$227,163
Stock-based compensation expense——5,572——5,572
Employee stock purchase plan expense——54——54
Exercise of stock options41,908—95——95
Net unrealized gain on marketable securities———582—582
Net loss————(34,555)(34,555)
Balances at September 30, 202457,288,319$4$599,982$464(401,539)$198,911
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · (Loss) Income · Deficit · Equity
Balances at December 31, 202354,992,784$4$559,176$347(305,632)$253,895
Issuance of shares under at-the-market offering, net of issuance costs of $1661,772,278—22,787——22,787
Stock-based compensation expense——15,818——15,818
Exercise of stock options359,897—1,110——1,110
Issuance of shares under the employee stock purchase plan70,701—650——650
Employee stock purchase plan expense——441——441
Vesting of restricted stock awards92,659—————
Net unrealized gain on marketable securities———117—117
Net loss————(95,907)(95,907)
Balances at September 30, 202457,288,319$4$599,982$464(401,539)$198,911

Condensed Consolidated Statements of Cash Flows

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.